Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Xun Hui Yeo"'
Autor:
Xun Hui Yeo, Vignesh Sundararajan, Zhengwei Wu, Zi Jin Cheryl Phua, Yin Ying Ho, Kai Lay Esther Peh, Yi-Chia Chiu, Tuan Zea Tan, Dennis Kappei, Ying Swan Ho, David Shao Peng Tan, Wai Leong Tam, Ruby Yun-Ju Huang
Publikováno v:
Communications Biology, Vol 6, Iss 1, Pp 1-6 (2023)
Externí odkaz:
https://doaj.org/article/4669c9aed0f141f9b131ea498542c898
Autor:
Xun Hui Yeo, Vignesh Sundararajan, Zhengwei Wu, Zi Jin Cheryl Phua, Yin Ying Ho, Kai Lay Esther Peh, Yi-Chia Chiu, Tuan Zea Tan, Dennis Kappei, Ying Swan Ho, David Shao Peng Tan, Wai Leong Tam, Ruby Yun-Ju Huang
Publikováno v:
Communications Biology, Vol 6, Iss 1, Pp 1-15 (2023)
Abstract AXL is a receptor tyrosine kinase that is often overexpressed in cancers. It contributes to pathophysiology in cancer progression and therapeutic resistance, making it an emerging therapeutic target. The first-in-class AXL inhibitor bemcenti
Externí odkaz:
https://doaj.org/article/e4c51514b6d442e4b1c53e454bfbf0d3
Publikováno v:
Cancers, Vol 13, Iss 6, p 1316 (2021)
Cancer metabolism is a hallmark of cancer. Metabolic plasticity defines the ability of cancer cells to reprogram a plethora of metabolic pathways to meet unique energetic needs during the various steps of disease progression. Cell state transitions a
Externí odkaz:
https://doaj.org/article/5e2f5d83835e4bfab7cd09a5517e913f
Autor:
Xiaosai Yao, Jing Han Hong, Amrita M. Nargund, Michelle Shu Wen Ng, Hong Lee Heng, Zhimei Li, Peiyong Guan, Masahiro Sugiura, Pek Lim Chu, Loo Chien Wang, Xiaofen Ye, James Qu, Xiu Yi Kwek, Jeffrey Chun Tatt Lim, Wen Fong Ooi, Joanna Koh, Zhenxun Wang, You-Fu Pan, Yan Shan Ong, Kiat-Yi Tan, Jian Yuan Goh, Sheng Rong Ng, Luca Pignata, Dachuan Huang, Alexander Lezhava, Su Ting Tay, Minghui Lee, Xun Hui Yeo, Wai Leong Tam, Sun Young Rha, Shang Li, Ernesto Guccione, Andrew Futreal, Jing Tan, Joe Poh Sheng Yeong, Wanjin Hong, Robert Yauch, Kenneth Tou-En Chang, Radoslaw M. Sobota, Patrick Tan, Bin Tean Teh
Publikováno v:
Nature Cell Biology. 25:765-777
Autor:
Ruby Yun-Ju Huang, Xun Hui Yeo, Zhengwei Wu, Cheryl Phua, Yin Ying Ho, Kai Lay Esther Peh, Yi-Chia Chiu, Dennis Kappei, Ying Swan Ho, Wai Leong Tam
AXL is a receptor tyrosine kinase that is often overexpressed in cancers. It contributes to pathophysiology in cancer progression and therapeutic resistance, making it an emerging therapeutic target. The first-in-class AXL inhibitor bemcentinib (R428
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07ad0f4cfb6123c0dbae291cee902b61
https://doi.org/10.21203/rs.3.rs-1765179/v1
https://doi.org/10.21203/rs.3.rs-1765179/v1
Publikováno v:
Cancers
Cancers, Vol 13, Iss 1316, p 1316 (2021)
Cancers, Vol 13, Iss 1316, p 1316 (2021)
Simple Summary Metabolic adaptation by cancer cells is enabled through the rewiring of metabolic processes, thereby allowing them to survive and thrive in diverse tissue microenvironments. It is also exploited to maintain cancer stemness, drive epith
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::966261ff3e1922f7b7ce628f6b411844
https://hdl.handle.net/10356/151837
https://hdl.handle.net/10356/151837
Publikováno v:
Cancer Research. 80:4198-4198
AXL is a receptor tyrosine kinase that is often overexpressed in many cancers. It contributes to tumor progression, metastasis and drug resistance through activating downstream signaling cascades, making it an emerging therapeutic target. Moreover, t